What this whole patent discussion is missing is the part about being a licensed drug by the various regulatory authorities.
Part of a drug NDA submission is the information about where it will be made, what standards the facility will be using, quality control issues etc.
Somehow this discussion seems to be based on the idea that any drug manufacturer could make the drug and sell it. That is simply not the case. People seem to think without full patent protection it is like a drug suddenly becoming a generic which can be made by other companies without licensing. Even generic drugs have to go through an approval process to demonstrate equivalent effectiveness. 2-73 will have to be approved by the EUA for sales in the EU and the TGA for sales in Australia. Each of those approvals conveys specific protections for Anavex from competitors making 2-73.
Patents are nice. Anavex would like to have complete patent protection. however patents are not the only protection or even the strongest protection for Anavex and 2-73.
Market Data 
Markets 
AI
